thiotepa has been researched along with Kidney Failure, Chronic in 1 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a patient with chronic renal failure and transitional cell carcinoma, in whom a nephrogenic adenoma of the bladder was diagnosed after a course of intravesical thiotepa treatment." | 7.68 | Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa. ( Embon, OM; Gold, CH; Sazbon, A; Turani, H, 1990) |
| "We describe a patient with chronic renal failure and transitional cell carcinoma, in whom a nephrogenic adenoma of the bladder was diagnosed after a course of intravesical thiotepa treatment." | 3.68 | Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa. ( Embon, OM; Gold, CH; Sazbon, A; Turani, H, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Embon, OM | 1 |
| Turani, H | 1 |
| Gold, CH | 1 |
| Sazbon, A | 1 |
1 other study available for thiotepa and Kidney Failure, Chronic
| Article | Year |
|---|---|
Nephrogenic adenoma in a patient with chronic renal failure associated with intravesical treatment with thiotepa.
Topics: Adenoma; Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Failure, Chronic | 1990 |